Investment Rating - The investment rating for BeiGene is "Buy" with a target price of US$345.00, indicating an expected share price return of 48.5% [2][4]. Core Insights - BeiGene is transitioning to a global pharmaceutical player, officially changing its name to BeOne Medicines on May 23, 2025. The product Brukinsa has outperformed competitors Calquence and Imbruvica in quarterly sales in the US, contributing significantly to the overall growth of the BTKi class [1][2]. - The company achieved GAAP profitability in Q1 2025 and reiterated its FY25 guidance, projecting revenues between US$4.9 billion and US$5.3 billion, with GAAP operating expenses between US$4.1 billion and US$4.4 billion. The company has a robust pipeline of late- and early-stage catalysts that are expected to drive future growth [1][2]. Summary by Sections Financial Performance - In Q1 2025, BeiGene achieved positive GAAP operating income of US$11 million, marking a significant milestone for the company [1]. - The company has set a revenue guidance for FY25 between US$4.9 billion and US$5.3 billion, with operating expenses projected between US$4.1 billion and US$4.4 billion [1]. Market Position - Brukinsa has surpassed both Calquence and Imbruvica in US quarterly sales, driving over 100% of the net 11% year-over-year growth in the BTKi class, while Imbruvica saw a contraction of approximately 13% and Calquence only a 3% growth [1]. - The transformation into a global pharmaceutical entity is expected to enhance BeiGene's market position and investor appeal [1]. Valuation - The target price of US$345.00 is derived from a discounted cash flow (DCF) analysis, utilizing a weighted average cost of capital (WACC) of 9% and a terminal growth rate of 2.5% post-2032 [4].
花旗：百济神州-长期布局前景良好。百悦泽美国季度销售额超越阿卡替尼和伊布替尼，重申买入